ArticleScientific reports2025
Integrated bioinformatics analysis identifies CHAD association with osteoporosis and in vitro chondrogenic effects of Wogonin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP), characterized by reduced bone density and increased fracture risk. Current therapies have limitations due to side effects and variable efficacy, necessitating exploration of novel therapeutic targets and alternatives like Traditional Chinese Medicine (TCM). The molecular mechanisms driving OP remain incompletely understood. This study utilized integrated bioinformatics approaches to identify potentially dysregulated genes in OP and explored in vitro effects of TCM compounds targeting top identified genes. Differentially expressed genes (DEGs) associated with OP were identified by integrating bulk and single-cell RNA sequencing datasets. Potential therapeutic compounds targeting selected DEGs were screened from a TCM database using molecular docking to predict binding affinities. Based on highest binding scores, two compounds were selected for experimental validation. Their effects on chondrogenic differentiation, relevant to the known function of the identified target genes CHAD and COL2A1, were assessed in vitro using ATDC5 cells. Integrated bioinformatics analysis consistently identified CHAD and COL2A1 as significantly downregulated genes in OP datasets, and they were upregulated after teriparatide injection. Molecular docking predicted binding affinities of several TCM compounds to CHAD and COL2A1, with tetrandrine and wogonin showing the highest binding affinities. They were selected for chondrogenesis and qRT-PCR validation, and wogonin was experimentally demonstrated to have better chondrogenic differentiation effects in vitro. This study employed a multi-omics bioinformatics approach to identify CHAD as a potential hub gene of interest associated with osteoporosis. Preliminary in vitro experiments showed that wogonin modulates chondrogenic differentiation, a process related to CHAD's function, suggesting potential avenues for further investigation into OP therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.